Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosisCASE REPORT Open Access Ruxolitinib improves symptoms and quality of life in a patient

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseT h e n e w e ngl a nd j o u r na l o f m e dic i n e n engl j med 385;3 nejm.org July 15, 2021228

untitledMyeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety

untitledMyeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib clinicohematologic responses, quality-of-life changes and safety

Novel therapeutics in myeloproliferative neoplasmsREVIEW Abstract Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinibTreatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib Brooke Rothstein, BA,a

Review began 05/24/2022 Review ended 08/05/2022 Published 08/16/2022 © Copyright 2022 Magazzino et al. This is an open access article distributed under the terms of